Rixathon Indications/Uses

Non-Hodgkin's Lymphoma: RIXATHON is indicated for the treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphomas.
RIXATHON is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma (DLCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy.
RIXATHON is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with CVP chemotherapy.
RIXATHON maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Chronic Lymphocytic Leukaemia: RIXATHON is indicated in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid Arthritis: RIXATHON in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.